[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596270":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":46,"collaborators":21,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":21,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":21,"enrollmentInfo":59,"targetDuration":21,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":34,"whyStopped":21,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment with Gemcitabine plus Nab-Paclitaxel and mFOLFIRINOX","EXPERIMENTAL","Patient has been diagnosed with borderline resectable pancreatic ductal adenocarcinoma (pancreatic cancer) and has not received systemic or radiation therapy. Treating physician has recommended neoadjuvant (pre-operative) chemotherapy and radiation, prior to surgery.",[13,14],"Drug: Nab-paclitaxel + Gemcitabine","Drug: modified FOLFIRINOX (mFOLFIRINOX)",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Nab-paclitaxel + Gemcitabine","Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"modified FOLFIRINOX (mFOLFIRINOX)","Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Cancer Research Nurse","CONTACT","800-639-6918","cancer.research.nurse@hitchcock.org",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":21},"RECRUITING","Lebanon","New Hampshire","03756","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-72.25176,43.64229,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Gabriel A. Brooks","Principal Investigator","100596270","phase-2-24bro681--alternating-gnp-and-mfolfirinox-for-br-pdac-100596270",false,"NCT07043270","24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of BR-PDAC. The resectability should be officially determined with surgical oncologists at the Dartmouth Cancer Center (DCC) GI multidisciplinary Tumor Board based on NCCN Guidelines Version 2.2024 Pancreatic Adenocarcinoma.\n* Patients must be able and willing to provide informed consent.\n* Contrast-enhanced CT scan of the chest, abdomen, and pelvis performed within 45 days before registration.\n* ECOG Performance Status: 0-1.\n* Females of childbearing potential must have a negative pregnancy test done ≤ 14 days prior to study enrollment, and must agree to use a highly effective method of contraception throughout the course of protocol therapy.\n\nExclusion Criteria:\n\n* Any prior receipt of chemotherapy or radiation therapy for PDAC.\n* Known DPYD poor metabolizer genotype.\n* Known BRCA1\u002F2 or PALB2 mutations. If they are found to have BRCA1\u002F2 or PALB2 mutation after inclusion to the trial, the participant will be taken off of protocol therapy (since platinum-containing therapy is preferred for these patients).\n* Any confirmed second malignancy that is likely to require systemic therapy during the study period, in the opinion of the enrolling investigator.\n* Any of the following baseline laboratory abnormalities:\n\n  * Absolute neutrophil count (ANC) \\\u003C 2,500\u002Fmm3\n  * Platelet count \\\u003C 100,000\u002Fmm3\n  * Hemoglobin \\\u003C 7 g\u002FdL\n  * Creatinine \\> 1.5 x upper limit of normal (ULN)\n  * Total bilirubin \\> 1.5 x ULN\n  * AST\u002FALT \\> 5 x ULN\n* Any peripheral sensory neuropathy that meaningfully impairs performance of instrumental activities of daily living, as evaluated by the enrolling investigator.\n* Patients who are unable to provide informed consent.\n* Patients who are pregnant or breastfeeding.\n* Patients who are incarcerated.","ALL","18 Years",{"count":60,"type":61},35,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.",[67],"Pancreas Adenocarcinoma",[69,70,71,72,73,74,75],"mFOLFIRINOX","Gemcitabine","Nab-Paclitaxel","Neoadjuvant alternating chemotherapy","Resectable Pancreatic cancer","BR-PDAC","Pancreatic Cancer","2025-10-16",{"date":78,"type":79},"2025-10-20","ACTUAL",{"date":81,"type":79},"2025-09-29",{"date":83,"type":61},"2029-07-01",{"name":5,"class":6},1]